Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genomic mapping reveals cisplatin disruption of protein phosphorylation signalling genome-wide.

Metallomics : integrated biometal science·2026
Same author

In Vivo Imaging of a Photoactivatable Platinum Prodrug by Metal-Centered Radiolabeling.

Journal of the American Chemical Society·2026
Same author

A Correlative X‑ray Bioimaging Triad for Metals in Biomedical Research.

Chemical & biomedical imaging·2026
Same author

In Situ Lipid Interactions of an Anticancer Metal Complex.

Inorganic chemistry·2026
Same author

Multichiral Half-Sandwich Ru(II) and Os(II) Anticancer Complexes Containing a Glutathione Synthesis Inhibitor.

Organometallics·2025
Same author

Synthetic methods for key precursors of biologically active dimethylsulfoxide ruthenium complexes.

Dalton transactions (Cambridge, England : 2003)·2025

Related Experiment Video

Updated: May 18, 2026

Radiosynthesis of 1-(2-[18F]Fluoroethyl)-L-Tryptophan using a One-pot, Two-step Protocol
08:33

Radiosynthesis of 1-(2-[18F]Fluoroethyl)-L-Tryptophan using a One-pot, Two-step Protocol

Published on: September 21, 2021

Tryptophan switch for a photoactivated platinum anticancer complex.

Jennifer S Butler1, Julie A Woods, Nicola J Farrer

  • 1Department of Chemistry, University of Warwick, Coventry CV4 7AL, UK.

Journal of the American Chemical Society
|September 21, 2012
PubMed
Summary
This summary is machine-generated.

The platinum(IV) complex trans,trans,trans-[Pt(N3)2(OH)2(py)2] (1) shows potent cancer cell toxicity upon blue light irradiation. This effect is switched off by l-tryptophan, which quenches azidyl radical formation.

More Related Videos

Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents
07:20

Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents

Published on: May 28, 2014

In Vitro and In Vivo Evaluation of Photocontrolled Biologically Active Compounds - Potential Drug Candidates for Cancer Photopharmacology
13:17

In Vitro and In Vivo Evaluation of Photocontrolled Biologically Active Compounds - Potential Drug Candidates for Cancer Photopharmacology

Published on: September 29, 2023

Related Experiment Videos

Last Updated: May 18, 2026

Radiosynthesis of 1-(2-[18F]Fluoroethyl)-L-Tryptophan using a One-pot, Two-step Protocol
08:33

Radiosynthesis of 1-(2-[18F]Fluoroethyl)-L-Tryptophan using a One-pot, Two-step Protocol

Published on: September 21, 2021

Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents
07:20

Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents

Published on: May 28, 2014

In Vitro and In Vivo Evaluation of Photocontrolled Biologically Active Compounds - Potential Drug Candidates for Cancer Photopharmacology
13:17

In Vitro and In Vivo Evaluation of Photocontrolled Biologically Active Compounds - Potential Drug Candidates for Cancer Photopharmacology

Published on: September 29, 2023

Area of Science:

  • Inorganic Chemistry
  • Photochemistry
  • Cancer Therapeutics

Background:

  • Platinum(IV) complexes are investigated for cancer therapy.
  • Photoactivated platinum complexes can exhibit potent cytotoxicity.

Purpose of the Study:

  • To investigate the mechanism of photocytotoxicity of a specific Pt(IV) complex.
  • To explore the role of l-tryptophan in modulating this photocytotoxicity.

Main Methods:

  • Electron Paramagnetic Resonance (EPR) spectroscopy
  • Nuclear Magnetic Resonance (NMR) spectroscopy
  • Spin trapping techniques

Main Results:

  • The Pt(IV) complex trans,trans,trans-[Pt(N3)2(OH)2(py)2] (1) is cytotoxic to cancer cells under visible light.
  • l-tryptophan (l-Trp) at low doses (500 microM) inhibits this photocytotoxicity.
  • EPR and NMR studies indicate l-Trp quenches azidyl radical formation by acting as an electron donor.

Conclusions:

  • l-tryptophan can control the activity of photochemotherapeutic azido Pt(IV) drugs.
  • The dual attack mechanism involving radicals and Pt(II) photoproducts contributes to the potency of these platinum complexes.